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To improve the clinical value of ambulatory Holter electrocardio-
graphic (ECG) monitoring as a tool of antiarrhythmic therapy 
control, a new statistical model was developed. In a patient group 
at increased risk of sudden cardiac death, the spontaneous vari-
ability of ventricular arrhythmias was assessed, with simultaneous 
consideration of single ventricular premature complexes, couplets 
and salvos. The study included 100 patients who suffered from 
coronary heart disease or idiopathic dilated cardiomyopathy and 
for whom >30 ventricular premature complexes/h and couplets 
had been demonstrated on the last Holter ECG before the study. 
Between 3 and 12 Holter recordings were made for each patient in 
a drug-free state; the mean follow-up period was 260 days 
(maximum 1,403). The mean hourly values of the ectopic events 
(EE) were assessed separately for ventricular premature com-
plexes, couplets and salvos. The spontaneous variability (SV) was 
calculated for single ventricular premature complexes, couplets 
and salvos as SV = log (EEd8y 2 + O.OI/EEday 1 + 0.01) and linked 
in one, two and three dimensions. 
Compared with the consideration of only one type of arrhyth-
mia (one-dimensional model), the simultaneous use of two or three 
types of arrhythmia (two- or three-dimensional model) resulted in 
Because the occurrence of ventricular arrhythmias is subject 
to great variation, it is difficult to judge the effect of antiar-
rhythmic treatment in a given case. According to biostatis-
tical studies (1-9) published to date, single ventricular pre-
mature complexes must be reduced by about 70%, couplets 
by 2:90% and salvos by 2:95%. These criteria are valid 
assuming a therapy duration of :51 or 2 weeks (1-3,7). If 
therapy lasts longer, these values increase progressively 
(5,8-10), making it almost impossible to evaluate an antiar-
rhythmic therapy> 3 months in duration by means of Holter 
electrocardiographic (ECG) monitoring. 
To improve the value of Holter ECG monitoring as a tool 
for therapy control, we analyzed available biostatistical 
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considerably lower reduction and aggravation rates as sufficient 
proof of drug effects. With control intervals up to 1 week, the 
one-dimensional model yielded reduction rates for ventricular 
premature complexes, couplets and salvos of -63%, -90% and 
-95%, respectively. In contrast, with the three-dimensional 
model, the rates were -28%, -72% and -88%. The correspond-
ing aggravation values were +370, + 1,114% and +2,189% 
versus +38%, +256% and +747%. With longer control inter-
vals, these values increased progressively (in the interval from 3 
months to 1 year, with the three-dimensional model, the rates 
were -71%, -93% and -96% and +240%, +1,253% and 
+2,482%). 
In conclusion, lower reduction rates are required to distinguish 
between spontaneous variations and therapy effects when the 
various forms of arrhythmia are assessed simultaneously than 
when they are assessed separately. The three-dimensional model 
not only facilitates future drug trials to determine antiarrhythmic 
drug efficacy, but also is important for controlling antiarrhythmic 
therapy in clinical practice. 
(J Am Coll CardioI1991;18:138-43) 
models for methodologic weaknesses. We found that the 
therapy criteria have always been calculated separately for 
ventricular premature complexes, couplets and salvos (1-9), 
although these types are correlated with each other to some 
extent. When one type of arrhythmia was examined, the 
other two types were disregarded. However, if a patient has 
two or all three forms of arrhythmia, it is unclear which of 
these should be considered and how they should be linked to 
allow for assessment of drug efficacy. 
If the correlation between the types of arrhythmia was 
high (r = 1), each single variable would suffice because it 
would contain the entire information on the others. In 
contrast, if there was no correlation at all (r = 0), each 
variable would have to be considered independently. In 
reality, the correlation is moderate so that the analysis of 
only one variable would result in assumption of drug ef-
ficacy, even though the other forms have decreased insuffi-
ciently, remained constant or even increased. In view of 
these methodologic limitations, which in our view contribute 
to the rather low signal to noise ratio for drug effects versus 
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Table 1. Clinical Data From the 100 Study Patients 
Symptoms 
Syncope 
History of resuscitation 
Underlying heart disease 
CHD 
History of myocardial infarction 
Bypass surgery 
LVEF(%) 
Beta-blocker therapy 
IDC 
LVEF (%) 
Arrhythmias (counts/h) 
VPCs 
Couplets 
Salvos 
17 
8 
47 
38 
12 
44.3 ± 14.5 
24 
53 
34.4 ± 12.0 
322.3 ± 341.3 
17.2 ± 31.7 
3.9 ± 25.8 
CHD = coronary heart disease; IDC = idiopathic dilated cardiomyopa-
thy; LVEF = left ventricular ejection fraction; VPCs = ventricular premature 
complexes. 
spontaneous variability, we developed an arrhythmia model 
that simultaneously evaluates all three arrhythmia variables, 
if available. 
Methods 
Study patients (Table 1). The inclusion criteria for the 
study were >30 ventricular premature complexes/h and 
couplets on the ambulatory 24 h ECG and evidence of 
coronary heart disease or idiopathic dilated cardiomyopa-
thy. The study group included 100 patients (79 men and 21 
women) aged 56 ± 12 years. This was the same group from 
which we collected data already published (8) on the spon-
taneous variability of ventricular arrhythmias over long time 
intervals. Forty-seven patients suffered from coronary heart 
disease and 53 had idiopathic dilated cardiomyopathy. The 
underlying heart disease had been documented by left heart 
catheterization or radionuclide ventriculography. Eighty-
seven patients showed not only ventricular premature com-
plexes and couplets, but also ventricular salvos. Forty-four 
patients received no antiarrhythmic therapy throughout the 
observation period; all were examined regularly as outpa-
tients. 
In the course of the study, 56 of the 100 patients were 
treated with antiarrhythmic drugs, either because they were 
known to have serious hemodynamic complications of ar-
rhythmia (such as syncope or ventricular fibrillation) or 
because they were taking part in a clinical study to assess the 
efficacy of antiarrhythmic drugs. For these patients, the 
calculations of spontaneous variability of single and complex 
ventricular premature complexes were based on Holter ECG 
findings recorded before the beginning of treatment or in 
phases free from therapy during the follow-up period, with a 
minimal interval of 5 days since the last administration of 
drugs. 
Follow-up. The follow-up period was an average of 260 
days (maximum 1,403 days); between 3 and 12 Holter 24-h 
ECG recordings were prepared per patient. In the analysis of 
spontaneous variability, all Holter recordings were used 
despite the different number of recordings per patient. This 
procedure did not bias the results, because a comparison 
with computations involving only one pair of Holter record-
ings for each patient revealed no significant differences. 
Holter ECG analysis. All Holter recordings were evalu-
ated with the aid of the arrhythmia computer ICR 6201G 3, 
which was reported to have a sensitivity >96% and an 
accuracy >94% in recognizing single and repetitive ventric-
ular premature complexes (11). In addition to the automatic 
analysis, miniaturized total printouts were prepared from all 
tapes (ICR Variprinter) and the computer findings were 
checked visually on a beat by beat basis. The number of 
ectopic events was stated separately for ventricular prema-
ture complexes, couplets and salvos as hourly mean values. 
Results 
Development of the Multidimensional Model 
One-dimensional model. The new multidimensional vari-
ability model is based on the one-dimensional ratio method 
previously developed by our working group (8,12). The 
"spontaneous" variability ratios (SV) were calculated sep-
arately for single ventricular premature complexes (VPCs), 
couplets (CpO and salvos (Slv): 
SV VPCs = log (VPCsday 2 + O.OIIVPCsday I + 0.01) 
SV Cpl = log (Cplday 2 + O.OIlCplday I + 0.01) 
SVSlv = log (Slvday2 + O.OIlSlvdaYI + 0.01) 
The 95% confidence intervals of these ratios ± 2 SD were 
calculated considering the fact that all mean values did not 
differ significantly from O. Therefore, only 5% of all sponta-
neous observations are outside this range, 2.5% being above 
and 2.5% below. A constant of +0.01 was added in each case 
to allow for mathematic transformation by taking the loga-
rithm even in the case of a reduction to O. 
When this model is applied to evaluate antiarrhythmic 
drug effects, the finding during therapy is compared with the 
finding before therapy. If the resulting ratio is within the 
spontaneous range, a therapy effect is improbable. If it is 
within the complementary range above or below, this indi-
cates proarrhythmia or antiarrhythmic efficacy. Arrhythmia 
events offewer than eight per day or 0.33/h were disregarded 
because of the threshold problem, which has been discussed 
in detail elsewhere (12). 
An analysis of the data set with respect to the underlying 
heart disease revealed no differences in spontaneous vari-
ability between patients with coronary heart disease and 
those with idiopathic dilated cardiomyopathy (13). This 
observation also held for the two- and three-dimensional 
criteria described later. 
Figure 1 shows the distribution of variability ratios sepa-
rately in terms of ventricular premature complexes, couplets 
and salvos on Holter ECG tracings recorded within I week. 
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Figure 1. Spontaneous variability (SY) ratios of single ventricular 
premature complexes (YPC's), couplets and salvos with control 
intervals of:Sl week duration. The gray areas each enclose 2.5% of 
the spontaneous observations with the "normal range," including 
95% in between. 
The data points diverged with increasing complexity of the 
arrhythmia; the spontaneous variability of single ventricular 
premature complexes was relatively low and that of salvos 
was clearly greater. Couplets assumed an intermediate po-
sition. Because the spontaneous variability of ventricular 
arrhythmias increased with longer time intervals between 
the Holter findings under comparison (5,8-10), the therapy 
criteria were calculated separately in four time ranges by 
analogy with our previous procedure (Table 2). 
Two-dimensional model. The variability ratios of ventric-
ular premature complexes, couplets and salvos correlated 
moderately with each other (r = 0.28 to 0.59) (Fig. 2). This 
resulted in elliptic point clouds when the variability ratios of 
two types of arrhythmia (for example, ventricular premature 
complexes and couplets) were plotted against each other 
(Fig. 3). 
There are no standard rules for delimiting the active areas 
of reduction and aggravation for a multivariate normal range. 
A variety of approaches are conceivable for defining a 
multidimensional 95% range for the spontaneous variations 
(14). For instance, an elliptic area that covers 95% of the 
spontaneous variability could be considered. In this case, all 
observations outside the ellipse would represent probable 
drug effects. However, this would mean that results with an 
opposite influence on the types of arrhythmia (for example, 
a decrease in ventricular premature complexes with a simul-
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Figure 2. Correlations between the spontaneous variability ratios of 
single ventricular premature complexes (SY vPCs) and couplets 
(SY Cpl); spontaneous variability ratios of single ventricular prema-
ture complexes and salvos (SY Slv), and spontaneous variability of 
couplets and salvos with control intervals of :S 1 week. 
taneous increase in couplets) would have to be regarded as a 
drug effect although it would not be possible to distinguish 
clearly between "effective reduction" and "aggravation." 
To better comply with clinical needs, we selected the 
areas at the two poles of the ellipse, one for assessing 
effective reduction (both ratios <0) and the other for assess-
ing aggravation (both ratios >0), where each area must cover 
2.5% of all spontaneous observations. Several delimitation 
procedures are possible here as well. An approach with fixed 
criteria for assessing drug efficacy has practical advantages. 
It leads automatically to rectangular shapes of the active 
areas (Fig. 3), which were delimited as follows. The major 
axis of the ellipse (equivalent to the first principal component 
Table 2. Criteria According to the One-Dimensional Model 
Control Reduction Criteria (%) Aggravation Criteria (%) 
Interval 
(days) VPCs Cpl Siv VPCs Cpl Slv 
1-7 -63 -90 -95 +370 + 1,114 +2,189 
8-90 -79 -94 -98 +570 +1,895 +4,650 
91-365 -92 -98 -98 +1,286 +6,153 +5,698 
>365 -98 -99 -99 +5,495 + 14,032 +9,650 
Cpl = couplets; Slv = salvos; VPCs = ventricular premature complexes. 
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Figure 3. Two-dimensional distribution of the variability ratios of 
single ventricular premature complexes (SY vPC's) and couplets 
(SY C I) with control intervals of $1 week. The point cloud can be 
envefoped by an ellipse whose major axis extends between the areas 
representing a simultaneous reduction (R) or aggravation (A). To 
delimit spontaneous variability and drug effect, two points were 
determined on the major axis, which are symmetric to center 0 and 
serve as comer points for two quarter planes parallel to the 
coordinate planes. These quarter planes extend from the poles of the 
ellipse into negative or positive infinity, including 2.5% of the 
spontaneous observations and limiting the sectors of the reduction 
and aggravation rates. 
line) was determined by factor analysis. In the next step, a 
two-dimensional integration program was used to determine 
two points on the major axis (symmetric to center 0), which 
served as corner points for two rectangles parallel to the 
coordinate planes, extending from the poles of the ellipse 
into negative or positive infinity and each containing 2.5% of 
the spontaneous observations. Analyzing the efficacy of a 
therapy in terms of the findings of two types of arrhythmia 
simultaneously, the criteria-taken alone-are less strict, 
but must be met simultaneously (Table 3). 
Three-dimensional model. The situation remains essen-
tially the same when one adds the third variable, the vari-
ability ratio of the salvos. By analogy with the two-
dimensional approach, two points were determined on the 
first principal component line with the aid of a three-
dimensional integration program. They served as corner 
points for two hyper-rectangles (that is, three-dimensional 
spaces) extending from the poles of the ellipsoid into nega-
Figure 4. Three-dimensional distribution of the variability ratios of 
single ventricular premature complexes (SY vPCs), couplets (SV CPI) 
and salvos (SY Slv) with control intervals of $1 week. The represen-
tation is analogous to that of Figure 3. The area to the left shows the 
effectivity criteria; the area to the right is that of the aggravation 
criteria. 
tive or posItive infinity and defining the reduction and 
aggravation rates (Fig. 4). 
When all three types of arrhythmia are used for evalua-
tion, the individual criteria are even "weaker" than with 
one- or two-dimensional calculation. For control intervals 
< 1 week in duration, single ventricular premature com-
plexes need be reduced by only 28%, couplets by 72% and 
salvos by 88% to confirm antiarrhythmic efficacy. For longer 
control intervals, these criteria become continuously stricter 
(as expected), but for a therapy lasting up to 1 year, it will 
presumably still be possible to prove the efficacy in many 
cases. The therapy criteria for all control intervals are listed 
in Table 4. 
Compared with the easily remembered guidelines cus-
tomary to date, the new criteria are relatively complex. 
Control intervals of varying lengths and diverging arrhyth-
mia profiles with one, two or three types of arrhythmia in an 
individual patient demand extensive tabular material, partic-
ularly if the assessment is to be made on different probability 
levels. We therefore developed a computer program that 
Table 3. Criteria According to the Two-Dimensional Model 
Control Reduction Criteria (%) Aggravation Criteria (%) 
Interval 
(days) VPCs/Cpl CpIlSlv VPCs/Cpl CpIlSlv 
1-7 -46 -86 -80 -90 +85 +618 +406 +870 
8-90 -58 -90 -89 -94 +140 +883 +781 +1,639 
91-365 -86 -96 -96 -96 +604 +2.199 +2,350 +2,697 
>365 -97 -97 -98 -98 +2,936 + 3,356 +4,952 +4,952 
Abbreviations as in Table 2. 
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Table 4. Criteria According to the Three-Dimensional Model 
Control Reduction Criteria (%) 
Interval 
(days) VPCs/CpIlSlv 
1-7 -28 -72 -88 
8-90 -41 -82 -93 
91-365 -71 -93 -96 
>365 -92 -96 -96 
Abbreviations as in Table 2. 
takes care of this work and can be used to gradually build up 
a patient data base. * 
Discussion 
Role of Holter ECG recordings in evaluating drug therapy. 
The cardinal question that concerns us is whether it is 
actually possible to improve survival among patients at risk 
by pharmacologic arrhythmia suppression. No randomized 
double-blind placebo-controlled drug trial (15-22) completed 
to date could establish any superiority of the tested antiar-
rhythmic drugs over placebo in patients at risk of sudden 
cardiac death. In recent years, the most frequent explanation 
for this disappointing outcome was that no individual testing 
of efficacy was performed. However, since the publication of 
the Cardiac Arrhythmia Suppression Trial (CAST) (16) in 
which patients receiving antiarrhythmic drugs had a poorer 
outcome than those receiving placebo despite individual 
drug titration, the role of Holter ECG monitoring in defining 
therapy effects is debatable. 
The CAST results (23,24) do not definitively disprove the 
arrhythmia suppression hypothesis because it is impossible 
to improve the excellent prognosis of the CAST placebo-
treated groups. Because premature abandonment of this 
hypothesis would deprive us of the only noninvasive evalu-
ation method currently available, further studies should be 
conducted in patients at higher risk than those enrolled in the 
CAST study (16). The hypothesis would be refuted only if 
new studies again revealed an excess mortality rate in the 
actively treated groups. 
One of the greatest problems in using Holter ECG monitor-
ing for antiarrhythmic therapy control is that measurement of 
arrhythmia suppression is complicated by the high spontane-
ous variability of ventricular arrhythmias. If there is, in fact, a 
correlation between pharmacologic arrhythmia suppression 
and survival, one can detect it only by assessing the changes in 
arrhythmia frequency with extreme accuracy. This goal can be 
achieved only if one has identified the potential shortcomings 
of the method and keeps them under control. 
Over the past decade, several working groups (5,8-
10,25,26) have developed biostatistical models for differen-
tiating spontaneous arrhythmia changes from true drug ef-
* The program is already available. Information can be obtained from the 
authors. 
Aggravation Criteria (%) 
VPCs/CpIlSlv 
+38 +256 +747 
+71 +447 +1,356 
+240 + 1,253 +2,482 
+ 1,115 +2,124 +2,568 
fects. It has been shown that spontaneous variability 
increases with longer control intervals (the time span be-
tween two Holter recordings that are being compared), 
making it almost impossible to evaluate long-term antiar-
rhythmic therapy without conducting a withdrawal test 
(5,8-10,25,26). 
Arrhythmia evaluation model to assess variability and 
effect oftherapy. In view ofthis unsatisfactory situation, we 
saw a definite need for a critical analysis of the existing 
biostatistical models. We consider the most serious limita-
tion of these models (1-9) to be that the therapy criteria were 
calculated separately for ventricular premature complexes, 
couplets and salvos, even though there is a moderate corre-
lation among these three types of arrhythmia. When one 
type of arrhythmia was evaluated, the changes in the other 
two types were disregarded despite the information they 
contain about each other. Therefore, we decided to develop 
an arrhythmia evaluation model that takes into account all 
available variables when calculating spontaneous variability. 
If a patient shows two types of arrhythmia at a sufficient 
frequency (that is, more than 8 events/day [12]), this consid-
erably facilitates the assessment of antiarrhythmic effects. 
The necessary percent changes for proving aggravations and 
reductions are clearly lower than if the variables are consid-
ered separately. Discordant changes in the frequency of two 
arrhythmia types are not taken as evidence of drug response 
(which would be clearly false positive). This considerably 
improves the accuracy of antiarrhythmic drug assessment. 
When all three types of arrhythmia are present in one 
patient, it is possible to employ the three-dimensional model. 
The resulting therapy criteria are considerably less stringent 
than those derived one- or two-dimensionally. For instance, at 
control intervals < 1 week in duration, a reduction in ventric-
ular premature complexes by as little as 28% is sufficient to 
prove drug efficacy, provided that couplets and salvos are 
simultaneously suppressed by '2:.72% and 88%, respectively. In 
some patients with all three types of arrhythmia, one type 
(usually the salvos) will be below the threshold of8 events/day, 
whereas the others are above the threshold. In these cases, it is 
advisable to assume effective arrhythmia suppression only if 
the arrhythmia above the threshold meets the therapy criteria 
and that below the threshold is reduced to zero. 
If therapy lasts >1 year, even the new criteria will 
increase to unreachable levels. In this case, one should 
reconsider the strategy used to date. At the start of an 
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antiarrhythmic treatment, a type 1 error must primarily be 
considered, whereas during the course of treatment, the type 
2 error becomes significant. If, for example, during long-
term treatment the therapy criteria are not met (as a result of 
increasing spontaneous variability) despite continuing ar-
rhythmia reduction, the patient would have to be classified 
as a nonresponder. From a clinical point of view, however, 
it would be acceptable to continue regarding the patient as a 
responder. This would make it necessary to accept a lower 
statistical probability (p > 0.05). We consider this feasible, 
especially because any change in the therapy plan must be 
given careful thought for patients at high risk who have 
survived for> 1 year. Generally, long-term antiarrhythmic 
therapy can now be validated for up to 1 year in most 
patients. 
Clinical implications. The three-dimensional model could 
be employed in the design of future drug trials of antiarrhyth-
mic drug efficacy guided by Holter ECG monitoring. We 
hope that this will provide an answer to the important 
question of the clinical value of pharmacologic arrhythmia 
suppression, which is as yet unclear because of the method-
ologic weaknesses of previous biostatistical models. The 
role of Holter ECG monitoring in antiarrhythmic therapy 
control, which was questioned by some researchers after 
publication of the CAST study (16), can in our view be 
assessed only after an investigation has been made with an 
improved study design and, in particular, with optimal 
determination of the changes in arrhythmia frequency. 
The new criteria are also of considerable importance for 
assessing an individual patient in general and clinical prac-
tice. Because the clearly lower reduction rates make anti-
arrhythmic effects easier to recognize, the attending physi-
cian will in individual cases be able to avoid a dose increase 
into the toxic range or a change to a different drug with more 
serious side effects, thus contributing to the patient's safety. 
In terms of the aggravation rates, the new model provides 
practical criteria for the first time, an important fact in the 
light of the CAST result (16) of late proarrhythmia. 
Finally, there is the possibility of extending the present 
model to supraventricular arrhythmias. It may be a better 
method of assessing the frequency of atrial flutter, atrial 
fibrillation or atrioventricular node reentrant tachycardia 
than the methods currently available. On the basis of a 
simultaneous consideration of two or three variables that 
could include single premature atrial beats, short runs of 
"benign" atrial tachycardia or more sustained forms of 
supraventricular arrhythmia, the model would greatly en-
hance the field of antiarrhythmic assessment. 
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